{
    "clinical_study": {
        "@rank": "89076", 
        "arm_group": [
            {
                "arm_group_label": "Zydena 50mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo + Donepezil 5mg or 10mg"
            }, 
            {
                "arm_group_label": "Zydena 100mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether Zydena (Udenafil) has positive effect on\n      cognitive function in patients with Alzheimer's disease.\n\n      This study is a randomized, double blind, placebo-controlled multicenter study."
        }, 
        "brief_title": "Zydena on Cognitive Function of Alzheimer's Disease Patients", 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed written informed consent;\n\n          -  Male or female subjects 50 to 90 years of age;\n\n          -  Diagnosis of probable Alzheimer's disease according to National Institute of\n             Neurological Disorders and Stroke and the Alzheimer's Disease and Related Disorders\n             Association (NINCDS/ADRDA) criteria;\n\n          -  A Mini-Mental State Examination (MMSE) score of \u226510 and \u226426;\n\n          -  Global Clinical Dementia Rating \u2265 0.5;\n\n          -  Mild to moderate (not severe) white matter hyperintensities on brain MRI performed\n             within three years from screening;\n\n          -  Good enough hearing and visual function to complete neuropsychological tests\n\n          -  Caregivers living with patients or spending 10 or more hours a week with patients;\n\n          -  Stable dose of donepezil (5mg to 10mg) for at least 60 days;\n\n          -  If patients have been on memantine, it should be washed out for at least 60 days;\n\n          -  Medications including anxiolytics, antipsychotics, and hypnotics may be taken if the\n             dose has been stable for at least two weeks\n\n        Exclusion Criteria:\n\n          -  History of stroke within 6 months;\n\n          -  Previous diagnosis of severe (more than 80%) intracranial artery stenosis;\n\n          -  History of heart failure, ischemic heart disease (myocardial infarction, unstable\n             angina, and stable angina), hypertrophic cardiomyopathy, and life-threatening\n             arrhythmia;\n\n          -  Previous history of coronary artery bypass graft surgery;\n\n          -  Severe symptom of orthostatic hypotension (orthostatic syncope or presyncope),\n             especially when patients take alpha-adrenergic blocker (Alfuzosin, Doxazosin,\n             Naftopidil, Tamsulosin, Terazosin, Arotinolol, Carvedilol, Labetalol, Trazodone,\n             typical and atypical antipsychotics);\n\n          -  Uncontrolled diabetes mellitus;\n\n          -  Proliferative diabetic retinopathy;\n\n          -  Severe hypotension (blood pressure less than 90/50mmHg) or severe hypertension (blood\n             pressure more than 170/100mmHg);\n\n          -  Hepatic dysfunction (AST or ALT more than three times of upper normal limit) or renal\n             dysfunction (serum creatinine more than 2.5mg/dL);\n\n          -  Retinitis pigmentosa;\n\n          -  Previous history of active peptic ulceration within one year before screening;\n\n          -  Hematodyscrasia susceptible to priapism including sickle cell anemia, multiple\n             myeloma, leukemia, and various bleeding disorders;\n\n          -  History of drug abuse;\n\n          -  Medication including nitrates/nitric oxide donor (ex: nitroglycerin, isosorbide\n             mononitrate, isosorbide dinitrate, amyl nitrate/nitrite, and Sodium nitroprusside),\n             androgen (ex: testosterone), anti-androgen, and anticoagulants;\n\n          -  Current cancer chemotherapy;\n\n          -  Usage of PDE5i (Zydena, Viagra\u00ae, Levitra\u00ae, or Cialis\u00ae) within two weeks before study\n             start;\n\n          -  History of hypersensitive reaction to PDE5i (Zydena, Viagra\u00ae, Levitra\u00ae, or Cialis\u00ae)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "210", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01940952", 
            "org_study_id": "2012-03-065", 
            "secondary_id": "2012-03-065"
        }, 
        "intervention": [
            {
                "arm_group_label": "Zydena 50mg", 
                "intervention_name": "Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg", 
                "intervention_type": "Drug", 
                "other_name": "Zydena 50mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo + Donepezil 5mg or 10mg", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }, 
            {
                "arm_group_label": "Zydena 100mg", 
                "intervention_name": "Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg", 
                "intervention_type": "Drug", 
                "other_name": "Zydena 100mg"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Donepezil", 
                "Udenafil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 9, 2013", 
        "location": {
            "contact": {
                "email": "ed.ko@samsung.com", 
                "last_name": "Enda Go, Clinical Research Coordinator", 
                "phone": "82-2-3410-2868"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "135-710"
                }, 
                "name": "Samguns Medical Center"
            }, 
            "investigator": {
                "last_name": "Duk L. Na, MD. PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "Efficacy of Zydena (Udenafil) on Cognitive Function of Alzheimer's Disease Patients: A Randomized, Double Blind, Placebo-controlled Multicenter Study", 
        "overall_contact": {
            "email": "ed.ko@samsung.com", 
            "last_name": "Enda Go, Clinical Research Coordinator", 
            "phone": "82-2-3410-2868"
        }, 
        "overall_contact_backup": {
            "email": "dukna@naver.com", 
            "last_name": "Duk L. Na, MD. PhD", 
            "phone": "82-2-3410-3599", 
            "phone_ext": "3599"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "measured by ADAS-cog", 
            "measure": "Change in cognitive function", 
            "safety_issue": "No", 
            "time_frame": "from baseline to Week 12 and Week 24 after the administration of the medication"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01940952"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "Duk Lyul Na", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Measured by MMSE, Clinical Dementia Rating Sum of Boxes, ADCS-ADL, COWAT, Digit Symbol Coding, Trail Making Test-E", 
                "measure": "Change in cognitive function", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 12 and Week 24"
            }, 
            {
                "description": "Measured by Neuropsychiatric Inventory", 
                "measure": "Change in behavioral symptoms", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 12 and Week 24"
            }, 
            {
                "description": "Measured by FDG-PET", 
                "measure": "Change in brain function", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 12 and Week 24"
            }
        ], 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}